A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma

Response criteria for phase II studies of supratentorial malignant glioma.

David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations

Medicine, Oncology, Radiology +17

Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

S.M. O'Reilly, E.S. Newlands, M Brampton et al. · European Journal of Cancer · 1993 · 280 citations

Medicine, Oncology, Pharmacology +9

Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase.

David S. Duch, Mark Edelstein, Seaton W. Bowers et al. · PubMed · 1982 · 64 citations

Life Sciences, Biochemistry, Pharmacology +14

Oral piritrexim, an effective treatment for metastatic urothelial cancer

Ronald de Wit, JT Roberts, G. Stoter et al. · British Journal of Cancer · 1993 · 52 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.

Lynn G. Feun, René González, Niramol Savaraj et al. · Journal of Clinical Oncology · 1991 · 38 citations

Medicine, Oncology, Pharmacology +12